Reminder for Medpace Stock Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy MEDP?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden on the investors.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rate during the class period, leading to overly optimistic growth expectations among investors, which ultimately resulted in financial losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and successful track record in this field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 393.420
Low
462.00
Averages
569.17
High
660.00
Current: 393.420
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Q1 2026 Earnings Call Insights
- Cancellation Rate Increase: In Q1 2026, Medpace experienced a rise in cancellations, with backlog cancellations reaching the highest point in over a year, resulting in a net book-to-bill ratio of 0.88, indicating weakened market demand that could impact future revenue growth.
- Financial Performance: The company reported revenue of $706.6 million and net income per diluted share of $4.28 for the first quarter, while generating $151.8 million in cash flow from operating activities; however, the rising cancellation rate poses challenges to future revenue visibility, leading management to maintain unchanged guidance for 2026.
- Leadership Change: CEO Troendle announced that Jesse Geiger will depart, with Troendle resuming the role of President, a shift that may influence the company's strategic direction and execution capabilities moving forward.
- Market Outlook Uncertainty: While management remains optimistic about approximately $1.94 billion of backlog converting to revenue in the next 12 months, concerns over the ongoing rise in cancellation rates and risks associated with client mergers could adversely affect the company's long-term growth potential.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden on the investors.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rate during the class period, leading to overly optimistic growth expectations among investors, which ultimately resulted in financial losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and successful track record in this field.
See More
Reminder for Medpace Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Fee Structure: Investors joining the class action incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements regarding its cancellation rates during the class period, leading to overly optimistic growth expectations among investors and resulting in financial losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its expertise and success in this field, prompting investors to carefully select experienced legal counsel.
See More
Medpace Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Medpace Holdings, seeking damages for investors who purchased the company's securities between April 22, 2025, and February 9, 2026, reflecting significant investor concern over the company's financial transparency.
- False Statement Allegations: The complaint alleges that Medpace misrepresented its expected book-to-bill ratio as approximately 1.15 during earnings calls, despite internal information indicating otherwise, potentially leading investors to misjudge the company's future financial health.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by June 5, 2026, indicating that legal avenues provide opportunities for investors to recover losses and enhance oversight of corporate governance.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions for investors, emphasizing its expertise and successful track record in securities fraud class actions.
See More
Medpace Holdings Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm has announced a class action lawsuit against Medpace Holdings, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline for investors to contact the firm by June 5, 2026, to participate.
- False Statements Allegation: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, and when the truth emerged, investors suffered significant losses, indicating that the company's public statements were materially misleading throughout this timeframe.
- Opportunity for Loss Recovery: Affected shareholders are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to help investors understand their rights, highlighting the importance of investor participation in this case.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, underscoring the need for proactive engagement to protect their interests.
See More
Meta Strikes Major Chip Deal with AWS to Enhance AI Infrastructure
- Infrastructure Investment: Meta has signed a three-year deal with AWS to deploy hundreds of thousands of Graviton chips, aiming to enhance AI performance with an expected 60% better energy efficiency than traditional systems, showcasing Meta's strategic commitment to AI.
- Workforce Adjustment: Despite the massive infrastructure investment, Meta announced a 10% workforce reduction, indicating a shift in capital allocation from human resources to high-performance silicon, reflecting the company's focus on future technology demands.
- Intensifying Market Competition: This move by Meta comes as competitors like Alphabet and Microsoft accelerate their internal hardware development, highlighting the urgency for Meta to secure computing capacity, which could reshape the industry landscape.
- CPU Renaissance: Intel has noted that central processors are re-emerging as the foundation for AI, and Meta's choice of Graviton chips over specialized accelerators indicates confidence in general-purpose processors, potentially driving growth across the semiconductor sector.
See More
Medpace Q1 2026 Earnings Call Insights
- Cancellation Rate Increase: In Q1 2026, Medpace experienced a rise in cancellations, with backlog cancellations reaching the highest point in over a year, resulting in a net book-to-bill ratio of 0.88, indicating weakened market demand that could impact future revenue growth.
- Financial Performance: The company reported revenue of $706.6 million and net income per diluted share of $4.28 for the first quarter, while generating $151.8 million in cash flow from operating activities; however, the rising cancellation rate poses challenges to future revenue visibility, leading management to maintain unchanged guidance for 2026.
- Leadership Change: CEO Troendle announced that Jesse Geiger will depart, with Troendle resuming the role of President, a shift that may influence the company's strategic direction and execution capabilities moving forward.
- Market Outlook Uncertainty: While management remains optimistic about approximately $1.94 billion of backlog converting to revenue in the next 12 months, concerns over the ongoing rise in cancellation rates and risks associated with client mergers could adversely affect the company's long-term growth potential.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden on the investors.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rate during the class period, leading to overly optimistic growth expectations among investors, which ultimately resulted in financial losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and successful track record in this field.
See More
Reminder for Medpace Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Fee Structure: Investors joining the class action incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements regarding its cancellation rates during the class period, leading to overly optimistic growth expectations among investors and resulting in financial losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its expertise and success in this field, prompting investors to carefully select experienced legal counsel.
See More
Medpace Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Medpace Holdings, seeking damages for investors who purchased the company's securities between April 22, 2025, and February 9, 2026, reflecting significant investor concern over the company's financial transparency.
- False Statement Allegations: The complaint alleges that Medpace misrepresented its expected book-to-bill ratio as approximately 1.15 during earnings calls, despite internal information indicating otherwise, potentially leading investors to misjudge the company's future financial health.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by June 5, 2026, indicating that legal avenues provide opportunities for investors to recover losses and enhance oversight of corporate governance.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions for investors, emphasizing its expertise and successful track record in securities fraud class actions.
See More
Medpace Holdings Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm has announced a class action lawsuit against Medpace Holdings, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline for investors to contact the firm by June 5, 2026, to participate.
- False Statements Allegation: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, and when the truth emerged, investors suffered significant losses, indicating that the company's public statements were materially misleading throughout this timeframe.
- Opportunity for Loss Recovery: Affected shareholders are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to help investors understand their rights, highlighting the importance of investor participation in this case.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, underscoring the need for proactive engagement to protect their interests.
See More
Meta Strikes Major Chip Deal with AWS to Enhance AI Infrastructure
- Infrastructure Investment: Meta has signed a three-year deal with AWS to deploy hundreds of thousands of Graviton chips, aiming to enhance AI performance with an expected 60% better energy efficiency than traditional systems, showcasing Meta's strategic commitment to AI.
- Workforce Adjustment: Despite the massive infrastructure investment, Meta announced a 10% workforce reduction, indicating a shift in capital allocation from human resources to high-performance silicon, reflecting the company's focus on future technology demands.
- Intensifying Market Competition: This move by Meta comes as competitors like Alphabet and Microsoft accelerate their internal hardware development, highlighting the urgency for Meta to secure computing capacity, which could reshape the industry landscape.
- CPU Renaissance: Intel has noted that central processors are re-emerging as the foundation for AI, and Meta's choice of Graviton chips over specialized accelerators indicates confidence in general-purpose processors, potentially driving growth across the semiconductor sector.
See More
